none

CSIRO IS ON A HEALTH KICK

05-09-2017
by 
in 
CSIRO M2 programme

Breakthroughs and remarkable discoveries are expected from the new "M2" programme between CSIRO and Monash University, as the two scientific behemoths collaborate to "bring the best minds and technology together to turn great ideas into a reality for Australia’s flourishing medtech industry". 

As innovation continues to be the watchword for Australian industry, efforts by the government to reinvest in science and technology are continuing apace. 

“From life-changing cochlear implants, to life-saving vaccines, world-first 3D printed bone and tissue replacements, Australia has an incredible track record when it comes to medical technologies and pharmaceuticals,” Senator Arthur Sinodinos said.

“M2 will help to accelerate development of technology like this, not only vital for the improvement of the lives of Australians facing medial challenges, but also leading to job and economic growth for Australia.”

Supported by the Science and Industry Endowment fund, M2 aims to bridge the gap between Australia's many small- and medium-sized medical technology enterprises, and the often-exorbitant cost of prototyping and developing new products. 

M2 will be providing a research ecosystem for these companies, helping to transition new discoveries from the bench to prototyping, pre-clinical testing, industry evaluation and commercialisation.

“M2 leverages some of Australia’s best medtech expertise, experience and equipment,” CSIRO Director of Manufacturing Dr Keith McLean said.

“When a company comes to us we can use CSIRO and MHTP facilities to develop and analyse production scale prototypes, whilst the Monash Biomedical Imaging facility can provide advanced pre-clinical and clinical testing and imaging.”

With global populations ageing and emerging markets seeking better health care, there’s huge growth underway in the MTP sector. It’s expected to be worth almost $3 trillion by 2025, while $18 billion and 28,000 new jobs could be added to the Australian economy over the next eight years.

“Monash is determined to help build a new, globally competitive biomedical industry with our partners,” Monash University Provost and Senior Vice-President Professor Marc Parlange said.

“This initiative will deliver real health benefits to all Australians. Our healthcare spending is expected to almost double to 16 per cent of GDP by 2040. Cheaper and more effective medical solutions are better for our health and Australia’s financial future.”

Related news & editorials

  1. 27.07.2021
    27.07.2021
    by      In
    The past weekend saw the launch of a new campaign from Bapcor, Asia Pacific’s leading provider of vehicle parts, accessories, equipment and service. The campaign, called The unseen parts of every Australian journey, focuses on the role the firm plays in the lives of ordinary Australians.
    Coinciding... Read More
  2. 27.07.2021
    27.07.2021
    by      In
    Entries are closing soon for the Premier’s Sustainability Awards 2021, Victoria’s annual sustainability awards program.
    With less than a week to apply, the awards recognise and celebrate individuals, organisations and communities that are contributing to Victoria’s long term sustainability efforts... Read More
  3. 27.07.2021
    27.07.2021
    by      In
    Whereas the world’s first industrial robot was brought to life in 1962, it wasn’t until 2008 that the first collaborative robot (cobot) made its way onto the scene. As the name suggests, a cobot is a robot that is intended for direct human-robot interaction within a shared space. These robots are... Read More
  4. 22.07.2021
    22.07.2021
    by      In
    Cybercrime taps into the vulnerability of business systems and can pose a real threat to a robust supply chain. A sophisticated ransomware attack recently targeted the world’s largest meat processor. Following the business system breach, operations in the US and Australia were disrupted, resulting... Read More
Products
Suppliers